DSKYF Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 14:12):

Stats
Today's Volume	972.00
Average Volume	21 590.00
Market Cap	59.42B
EPS	$20.86 ( 2023-10-31 )
Last Dividend	$0.113 ( 2023-03-30 )
Next Dividend	$0 ( N/A )
P/E	49.19
ATR14	$0 (0.00%)

Daiichi Sankyo Company, Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Daiichi Sankyo Company, Financials

Annual	2023
Revenue:	$1 278.48B
Gross Profit:	$914.95B (71.57 %)
EPS:	$56.96

Q3	2024
Revenue:	$446.93B
Gross Profit:	$324.58B (72.62 %)
EPS:	$34.71

Q2	2024
Revenue:	$375.51B
Gross Profit:	$280.77B (74.77 %)
EPS:	$20.86

Q1	2024
Revenue:	$350.84B
Gross Profit:	$257.16B (73.30 %)
EPS:	$29.74

Financial Reports:

No articles found.

Daiichi Sankyo Company, Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.0940 (N/A)	$0 (N/A)	$0.113 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Daiichi Sankyo Company, Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.27 - Stable (5.33%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.0980	2014-03-27
Last Dividend	$0.113	2023-03-30
Next Dividend	$0	N/A
Payout Date	2011-12-01
Next Payout Date	N/A
# dividends	18	--
Total Paid Out	$1.801	--
Avg. Dividend % Per Year	0.00%	--
Score	3.24	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.27
Div. Directional Score	8.52	--

Next Divdend (Est)
(2024-09-23)

$0 Estimate 0.00 %

Dividend Stability

0.09 Very Bad

Dividend Score

3.24

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
NACB	Ex Dividend Junior	2023-08-15	Quarterly	0.00%
CTUY	Ex Dividend Junior	2023-05-24	Annually	0.00%
SYIEY	Ex Dividend Knight	2023-05-11	Annually	0.00%
HPGLY	Ex Dividend Junior	2023-05-04	Annually	0.00%
BCUCY	Ex Dividend Knight	2023-05-22	Annually	0.00%
OUKPY	Ex Dividend Knight	2023-05-04	Semi-Annually	0.00%
ECTM	Ex Dividend Junior	2023-05-19	Quarterly	0.00%
TSRYY	Ex Dividend Knight	2023-08-30	Semi-Annually	0.00%
JPNRF	Ex Dividend Junior	2023-09-28	Sporadic	0.00%
BYDDF	Ex Dividend Junior	2023-06-13	Sporadic	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.124	1.500	7.53	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0569	1.200	8.10	9.72	[0 - 0.3]
returnOnEquityTTM	0.121	1.500	9.77	10.00	[0.1 - 1]
payoutRatioTTM	0.362	-1.000	6.38	-6.38	[0 - 1]
currentRatioTTM	3.49	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	2.74	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.099	1.500	5.01	7.51	[0.2 - 2]
debtRatioTTM	0.0311	-1.500	9.48	-10.00	[0 - 0.6]
interestCoverageTTM	8.42	1.000	7.99	7.99	[3 - 30]
operatingCashFlowPerShareTTM	313.79	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	265.71	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.0642	-1.500	9.74	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.723	1.000	1.286	1.286	[0.2 - 0.8]
operatingProfitMarginTTM	0.0999	1.000	-0.00241	-0.00241	[0.1 - 0.6]
cashFlowToDebtRatioTTM	5.91	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.460	0.800	-0.267	-0.214	[0.5 - 2]
Total Score				11.77

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	49.19	1.000	5.13	0	[1 - 100]
returnOnEquityTTM	0.121	2.50	9.85	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	265.71	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.00654	1.500	9.84	0	[0 - 0.4]
operatingCashFlowPerShareTTM	313.79	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.362	1.500	6.38	-6.38	[0 - 1]
pegRatioTTM	0.0460	1.500	-3.03	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.400	1.000	2.50	0	[0.1 - 0.5]
Total Score				5.27

Daiichi Sankyo Company,

Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.